ClinConnect ClinConnect Logo
Search / Trial NCT06882551

Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients

Launched by KHYBER TEACHING HOSPITAL · Mar 16, 2025

Trial Information

Current as of April 22, 2025

Completed

Keywords

Intravitreal Bevacizumab Suprachoroidal Triamcinolone Diabetic Macular Edema

ClinConnect Summary

Patients were included in the study who were pseudophakic with center-involved (sub-foveal) diabetic macular edema. Those patients who had glaucoma history or IOP above 21 mm of Hg, Phakic, corneal opacity, vitreous hemorrhage, proliferative diabetic retinopathy, already received anti-VEGF injections, history of pan-retinal photocoagulation for proliferative diabetic retinopathy.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with center involving diabetic macular edema on optical coherence tomography
  • Exclusion Criteria:
  • Raised intraocular pressure
  • History of glaucoma
  • Corneal opacity
  • Vitreous hemorrhage
  • Proliferative diabetic retinopathy
  • Anti-VEGF injections in last 3 months
  • History of pan-retinal photocoagulation
  • Contraindications for anti-VEGF

About Khyber Teaching Hospital

Khyber Teaching Hospital is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. Located in Peshawar, Pakistan, the hospital serves as a pivotal center for medical education and training, providing comprehensive healthcare services to diverse populations. With a commitment to improving patient outcomes, Khyber Teaching Hospital engages in rigorous clinical research that adheres to the highest ethical standards, fostering collaboration among healthcare professionals, researchers, and academic institutions. The hospital aims to contribute significantly to medical science by exploring new treatments and therapies that address critical health challenges.

Locations

Peshawar, Khyber Pakhtunkhwa, Pakistan

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported